HCPLive Network

Young Males With HIV Face Risk of Hearing Loss

FRIDAY, March 1 (HealthDay News) -- HIV infection is significantly associated with an increased risk of developing sudden sensorineural hearing loss (SSHL), according to research published online Feb. 21 in JAMA Otolaryngology-Head & Neck Surgery.

Charlene Lin, of the University of California, in Berkeley, and colleagues conducted a retrospective, cohort, population-based study involving 8,760 Taiwanese patients with HIV and 43,800 control subjects to quantify the risk of developing SSHL in patients with HIV.

The investigators found that, in the 18- to 35-year-old group, patients with HIV infection had a 2.17-fold higher risk of SSHL than control patients. In men, the risk of developing SSHL was 2.23-fold higher in HIV-infected patients compared with control patients. However, this association was not found in patients older than 35 years of age.

"In conclusion, HIV infection is associated with a significantly increased risk of the development of SSHL in patients aged 18 to 35 years, particularly among men," the authors write. "Scheduled auditory examinations for patients with HIV to assess the presence of chronic hearing impairment are advised to enable the early detection of SSHL."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
By growing vaginal skin cells outside of the human body, a team of researchers has pinpointed which bacteria fight against HIV.
Disease burden, income, and funding levels are not always aligned in the allocation of development assistance resources, according to a study published online April 8 in Health Affairs.
Life expectancy among HIV-positive adults in the United States and Canada treated with combination antiretroviral therapy has greatly improved since 2000, with 20-year-olds now expected to live into their 70s, according to a study published online Dec. 18 in PLOS ONE.
Children diagnosed with group A Streptococcus (GAS) have no need to throw away their toothbrushes.
Use of the injectable contraceptive depot medroxyprogesterone acetate, common in areas such as sub-Saharan Africa with high HIV-1 prevalence, is associated with suppression of the immune response, according to a study published online Jan. 25 in Endocrinology.
Early in the course of primary HIV-1 infection, a 48-week session of antiretroviral therapy (ART) delays disease progression versus no ART; and initiation of ART more than four months after the estimated start date of HIV infection reduces the likelihood of CD4+ T-cell count recovery, according to two studies published in the Jan. 17 issue of the New England Journal of Medicine.
For patients with HIV, there is a negative correlation between drinking frequency and antiretroviral therapy (ART) adherence, according to a cross-sectional study published online in Patient Preference and Adherence.
More Reading